MDxHealth (MDXH) Stock Price, News & Analysis

Company Overview

MDxHealth NV is a molecular diagnostics company specializing in the development and commercialization of genomic-based tests for urologic cancers. Founded in 2004 and headquartered in Liège, Belgium, with a North American hub in Irvine, California, MDxHealth leverages advanced epigenetic and transcriptomic technologies to improve diagnostic accuracy and patient management. The company’s assays aim to address unmet clinical needs in prostate and bladder cancer by reducing unnecessary biopsies and guiding treatment decisions.

MDxHealth’s flagship product, SelectMDx, is a non-invasive urine-based test designed to assess the risk of clinically significant prostate cancer, helping physicians decide whether a biopsy is warranted. ConfirmMDx, a tissue-based epigenetic assay, identifies DNA methylation changes in prostate tissue to detect patients at risk of harboring aggressive disease missed by initial biopsy. In addition, the firm is advancing its next-generation blood-based IsoPSA test, which employs proprietary signal processing algorithms to distinguish benign from malignant prostate conditions and refine patient selection for further workup.

The company’s commercial footprint spans the United States, Europe and select markets in Asia Pacific. In North America, MDxHealth collaborates with leading urology practices, reference laboratories and payers to facilitate test adoption and reimbursement. Its European operations support clinical validation studies and market access initiatives across key territories, while strategic partnerships in Asia Pacific drive local engagement and regulatory approvals. MDxHealth continues to invest in real-world evidence generation and health economics research to demonstrate the clinical utility and cost-effectiveness of its assays.

Under the leadership of CEO James Voelkel and a seasoned executive team, MDxHealth remains committed to advancing precision diagnostics in urologic oncology. The company’s board of directors includes experts in molecular biology, diagnostics commercialization and health care policy, providing strategic guidance as MDxHealth expands its product portfolio and geographic reach. With multiple late-stage programs in development, MDxHealth seeks to strengthen its role as a partner to clinicians and patients in the global fight against cancer.

Key Stats

• Today's Range: $2.09 to $2.18
• 50-Day Range: $1.70 to $2.30
• 52-Week Range: $1.35 to $3.50
• Volume: 30,208 shs
• Average Volume: 90,181 shs
• Market Capitalization: $101.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.50
• Consensus Rating: Buy

MDxHealth Stock Analysis - MarketRank™

MDxHealth scored higher than 31% of companies evaluated by MarketBeat, and ranked 745th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MDxHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MDxHealth has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MDxHealth are expected to grow in the coming year, from ($1.15) to ($0.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MDxHealth is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MDxHealth is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MDxHealth has a P/B Ratio of 6.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.11% of the float of MDxHealth has been sold short.

Short Interest Ratio / Days to Cover

MDxHealth has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MDxHealth has recently increased by 0.73%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MDxHealth does not currently pay a dividend.

Dividend Growth

MDxHealth does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.11% of the float of MDxHealth has been sold short.

Short Interest Ratio / Days to Cover

MDxHealth has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MDxHealth has recently increased by 0.73%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for MDxHealth this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MDxHealth insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.70% of the stock of MDxHealth is held by insiders.

MDXH Stock Analysis - Frequently Asked Questions

How have MDXH shares performed this year?

MDxHealth's stock was trading at $2.37 at the beginning of 2025. Since then, MDXH shares have decreased by 9.7% and is now trading at $2.14.

How were MDxHealth's earnings last quarter?

MDxHealth SA (NASDAQ:MDXH) posted its earnings results on Wednesday, May, 14th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.06. The firm earned $24.29 million during the quarter, compared to the consensus estimate of $22.62 million. MDxHealth had a negative trailing twelve-month return on equity of 492.11% and a negative net margin of 41.02%.
Read the conference call transcript.

When did MDxHealth's stock split?

Shares of MDxHealth reverse split before market open on Friday, December 29th 2023.The 1-10 reverse split was announced on Monday, October 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did MDxHealth IPO?

MDxHealth (MDXH) raised $45 million in an initial public offering on Thursday, November 4th 2021. The company issued 3,750,000 shares at $12.00 per share.

How do I buy shares of MDxHealth?

Shares of MDXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MDxHealth own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MDxHealth investors own include Cognition Therapeutics (CGTX), LAVA Therapeutics (LVTX), Coeptis Therapeutics (COEP), PHX Minerals (PHX), PayPal (PYPL), Arcadia Biosciences (RKDA) and Alimera Sciences (ALIM).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MDXH
• CIK: 1872529
• Web: mdxhealth.com
• Phone: 324-364-2070
• Fax: 32042597875
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.50
• High Stock Price Target: $7.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +205.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.07 million
• Net Margins: -41.02%
• Pretax Margin: -40.47%
• Return on Equity: -492.11%
• Return on Assets: -23.00%

Debt

• Debt-to-Equity Ratio: 13.81
• Current Ratio: 2.00
• Quick Ratio: 1.92

Sales & Book Value

• Annual Sales: $90.05 million
• Price / Sales: 1.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.31 per share
• Price / Book: 6.85

Miscellaneous

• Outstanding Shares: 47,290,000
• Free Float: 46,484,000
• Market Cap: $100.49 million
• Optionable: Not Optionable
• Beta: 1.31